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Abstract
Background: To evaluate prognostic factors that may influence local control (LC) of T1N0 glottic cancer treated by
primary radiotherapy (RT) with 6 MV photons.
Methods: We retrospectively reviewed the medical records of 433 consecutive patients with T1N0 glottic cancer
treated between 1983 and 2005 by RT in our institution. All patients were treated with 6 MV photons. One
hundred and seventy seven (41%) patients received 52.5 Gy in 23 fractions with 2.5 Gy/fraction, and 256 (59%)
patients received 66 Gy in 33 fractions with 2 Gy/fraction.
Results: The median follow-up time was 10.5 years. The 10-year LC rates were 91% and 87% for T1a and T1b
respectively. Multivariate analysis showed LC rate was adversely affected by poorly differentiated histology (Hazard
Ratio [HR]: 7.5, p = 0.035); involvement of anterior commissure (HR: 2.34, p = 0.011); fraction size of 2.0 Gy (HR: 2.17,
p = 0.035) and tumor biologically effective dose (BED) < 65 Gy15 (HR: 3.38, p = 0.017).
Conclusions: The negative impact of anterior commissure involvement could be overcome by delivering a higher
tumor BED through using fraction size of > 2.0 Gy. We recommend that fraction size > 2.0 Gy should be utilized,
for radiation schedules with five daily fractions each week.
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Background
Laryngeal cancer is the third most common head and
neck (H&N) cancer in Hong Kong. The age-standar-
dized incidence rate was 2.3 per 100,000 [1] and is com-
parable to those of other developed countries like USA,
the Netherlands and Japan. In Hong Kong, around 95%
of early glottic cancer (GC) patients were treated by pri-
mary radiotherapy (RT) alone [2].
There is extensive published data regarding manage-
ment of early GC treated by RT with Cobalt-60 or 2-4
megavoltage (MV) photons beam, with local control
(LC) rates ranging from approximately 85-94% in T1N0
disease [3-5]. The reported treatment outcome of early
GC by primary irradiation with 6 MV photons is limited
and conflicting. Some authors reported comparable
results with lower energies [6,7] whereas others raised
concern about a poorer outcome [8,9]. We present our
institution’s experience in this report.
Methods
Patient characteristics
In mid 2010, we conducted a retrospective analysis of
laryngeal cancer patients referred to our center for radi-
cal treatment over a 26 year period between January
1983 to December 2005. A total of 1256 consecutive
patients were identified. This retrospective study was
approved by our Institutional Review Board and Ethics
committee. According to the Hong Kong Cancer Regis-
try, about a quarter of all laryngeal cancer cases diag-
n o s e di nH o n gK o n go v e rt h a tp e r i o dw e r et r e a t e di n
our institution. Out of the 1256 patients, there were 433
previously untreated patients with T1N0 GC. * Correspondence: chichungtong@hkcr.org
Department of Clinical Oncology, Queen Elizabeth Hospital, 30 Gascoigne
Road, Kowloon, Hong Kong
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All patients had full physical examination, routine blood
counts, renal and liver function tests, chest x ray, endo-
scopic examination and biopsy for histology diagnosis.
Computed tomography (CT) scan of larynx and neck
was performed in 412 (95%) patients. Patients were
restaged according to UICC TNM 2002 classification
[10]. Table 1 summarized the various patient, tumor
and treatment parameters.
Radiotherapy Treatment
All patients were treated exclusively with 6-MV photons
from linear accelerator (LA). They were treated in a
supine position, immobilized with a customized cobex
H&N cast. All patients received a continuous course of
RT with once-daily fractionation, 5 fractions per week.
All fields were equally weighted and treated in each
fraction.
Field size and set up
All patients were treated with parallel-opposed fields, to
cover the glottic larynx with 1-2 cm margins. The field size
was obtained by multiplying the field length by the field
width. It ranged from 22-38.5 cm
2 (median: 27.5 cm
2).
Typically, the superior border was put at around the top of
the thyroid cartilage, the inferior border at around the bot-
tom of the cricoid cartilage; the anterior border extended
beyond the skin surface and the posterior border placed at
the anterior edge of vertebral body of the cervical verteb-
rae. Elective nodal irradiation was not given. Optimized
wedge filters were used to improve the dose homogeneity.
0.5 cm thickness wax up bolus was used for diseases invol-
ving or close to the anterior commissure (AC). From Feb-
ruary 1990, doses were prescribed to the 100% isodose line
on a 2- dimensional plan derived from the plane of the
patient contour at the level of the isocenter.
Dose and fractionation
RT dose was prescribed at the midline along the central
axis or recalculated at the ICRU reference point. Between
the period of 1983-1988 and 1996-2005, patients were
treated with a fraction size of 2.0 Gy whereas during
1989-1995, a fraction size of 2.5 Gy was utilized because
of constraints in LA machine in our hospital.
We opted to compute the tumor biologically effective
dose (BED) by using the standard linear quadratic for-
mula (LQ) with time factors corrected: [11]
Tumor BED = nd(1 + d/[α/β]) − loge2(T − Tk)/αTp
where n fractions of d Gy are given in an overall time
of T days and kick off time (Tk) for tumor repopulation.
Table 1 Patient, tumor and treatment parameters
Parameters Patients no (%)
Sex
Male 413 (95.3%)
Female 20 (4.6%)
T stage
T1a 324 (74.8%)
T1b 109 (25.1%)
Grade
Well differentiated 154 (35.5%)
Mod differentiated 273 (63.0%)
Poorly differentiated 6 (1.3%)
AC involvement
Yes 197 (45.4%)
No 236 (54.1%)
Hemoglobin level
≤ 13 g/dL 45 (10.4%)
> 13 g/dL 388 (89.6%)
Field size (cm2)
< 30.5 215
30.5-35.5 165
≥ 35.5 53
A. Dose fraction size
2.5 Gy 177 (40.8)
Total dose (Gy)
55 30 (6.9)
57.5 134 (30.9)
60 13 (3.0)
Tx duration (days)
≤ 30 25 (5.7)
31-33 141 (32.5)
≥ 34 11 (2.5)
BEDcGy15 (cGy)
Median 6520
range 6058-6820
B. Dose fraction size
2.0 Gy 256 (59.1)
Total dose (Gy)
64 52 (12.0)
66 202 (46.6)
68 2 (0.46)
Tx duration (days)
≤ 45 48 (11.0)
46-50 203 (46.8)
≥ 51 5 (1.5)
BEDcGy15 (cGy)
Median 6340
range 6040-6700
Abbreviations: AC = Anterior Commissure, Tx: treatment,
BEDcGy15 : Tumor biologically effective dose
Tong et al. Radiation Oncology 2011, 6:53
http://www.ro-journal.com/content/6/1/53
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for tumor[13], Tp = average cell number doubling time
during continuing radiation, 3 days for tumor[14]. Alpha
(a) = 0.35 Gy
-1 [14][coefficient of non-repairable injury,
log cell kill (exponentially-based logs) per gray of dose].
One hundred and seventy-seven (40.8%) were treated
with a dose fraction size of 2.5 Gy, with total dose of
55-60 Gy (median: 57.5 Gy), within a treatment duration
of 30-38 days (median 31 days). The most commonly
used dose-fractionation schedule was 57.5 Gy in 23 frac-
tions. Tumor BEDGy15 ranged from 60.5 to 68.2 Gy15
(median = 65.2 Gy15).
Two hundred and fifty- six (59.1%) patients were trea-
ted with a dose fraction size of 2.0 Gy, with a total dose
of 64-68 Gy (median: 66 Gy), within a treatment dura-
tion of 44-58 days (median: 46). The most commonly
used dose-fractionation schedule was 66 Gy in 33 frac-
tions. Tumor BEDGy15 ranged from 60.4 to 67.0 Gy15
(median = 63.4 Gy15).
Follow up and assessment
All patients underwent evaluation of response to treat-
ment by endoscopy examination at 6 to 8 weeks after
completion of RT treatment. Patients were regularly
seen once every two or three months during the initial
2 years and then six-monthly up to 5 years and then
yearly thereafter.
Complications
Acute and chronic complications were scored according
to the Common Terminology Criteria for Adverse
Events version 3.0 [15].
Statistical analysis
Local and neck failure was defined as clinically/radiolo-
gical detectable disease in larynx and cervical lymph
node (LN) respectively. Distant metastasis (DM) was
defined as clinically or radiologically detectable disease
outside the larynx and cervical LN. Clinicopathologic
parameters that were analyzed included age (<61 vs.
61-70 vs. >71), gender (male vs. female), pre-treatment
hemoglobin (Hb) level (<13.0 vs. ≥13.0 g/dl), T sub-
stage (T1a vs. T1b), tumor grading (well vs. moderate
vs. poorly differentiated squamous cell carcinoma),
involvement of AC (yes vs. no). Treatment parameters
included dose fraction size (2.0 Gy vs. 2.5 Gy),
BEDGy15 given (< 65.0 Gy15 vs. ≥ 65.0 Gy15), treatment
field size in cm
2 (< 30.5 vs. 30.5 - 35.5 vs. > 35.5), and
treatment period (1983-1990 vs. 1991-2000 vs. 2001-
2005).
All time-related events were measured from date of
the first RT treatment. The actuarial local/neck failure
rate and ultimate local/neck failure rate were calculated
by the Kaplan-Meier method. Difference of the
endpoints stratified by the various prognostic factors
were evaluated by the Log- rank test.
Cox proportional hazard model was used for both uni-
variate and multivariate analysis to determine the hazard
ratios and significance of potential risk factors for local
control (LC). All statistical tests were two-sided and per-
formed at the 0.05 level of significance (p value). Only
factors with a level of significance less than 0.05 in uni-
variate analysis would be further analyzed in the multi-
variate analysis. We used SPSS, version 15.0, (SPSS Inc.,
Chicago, IL) for all statistical analyses.
Results
Local and Neck control
The median follow-up time was 10.5 years (range 3.3 -
26.6 years). The clinical course of this patient cohort is
shown in figure 1. The 5-year and 10-year LC rates for
T1a group were 92% and 91% respectively whereas
those for T1b group were 89% and 87% respectively
(figure 2a).
Complete response (CR) was achieved in 430 (99.3%)
patients, while 3 (0.7%) patients had residual disease/dis-
ease progression at vocal cord(s) at 8 weeks after com-
pletion of RT. Thirty-six (8.3%) among the 430 patients
who achieved CR had their first relapse observed at a
median interval of 15 months after completion of RT
treatment. All first relapses occurred in the laryngeal
Figure 1 Clinical Course. Abbreviations: pts = patients; RT =
radiotherapy.
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tant sites.
Salvage surgery after recurrence/residual disease
Of the 39 patients who developed local recurrence or
persistent disease, 36 were salvaged by total laryngect-
omy. Three patients refused or were not considered
medically fit for salvage treatment. Seven patients devel-
oped second relapse or progression as regional or dis-
tant metastasis despite total laryngectomy, resulting in
overall ultimate disease failure in 10 patients. This
resulted in an ultimate 10 year LC of 97%. Larynx pre-
servation was achieved in 394 (91%) patients.
Complications
RT was well tolerated by all patients. No patient had grade
III or IV toxicity that necessitated treatment interruption
>3 days, nasogastric tube feeding, intravenous fluid supple-
ment or tracheostomy. There is no clinical or radiological
chondroradionecrosis that warranted laryngectomy.
Factors affecting Local Control
On multivariate analysis, LC was adversely affected by
poorly differentiated histology (Hazard Ratio [HR]: 7.5,
p = 0.035); involvement of AC (HR: 2.34, p = 0.011);
fraction dose size of 2.0 Gy (HR: 2.17, p =0 . 0 3 5 )
and tumor BEDGy15 <6 5G y 15 (HR: 3.38, p = 0.017)
[table 2].
Figure 2b depicts LC rate according to presence of AC
involvement. There was a significant difference in LC
between those with presence of AC involvement and
without AC involvement (86% vs. 95% at 5 years, 85%
vs. 94% at 10 years (p = 0.011). Figure 2c depicts LC
rate according to fraction size. There was a significant
difference between the 2.0 Gy group and the 2.5 Gy
group (89% vs. 95% at 5 years; 87% vs. 95% at 10 year, p
= 0.035). Figure 2d depicts LC rate according to tumor
BEDGy15. There was a significant difference between the
group with tumor BED < 65 Gy15 vs. the group with
tumor BED ≥ 65 Gy15 (90% vs. 96% at 5 years; 88% vs.
96% at 10 years, p = 0.017).
Figure 2 Local control rate according to T sub-stage; AC involvement; Fraction size; tumor BEDGy15. a. T sub stage (T1a vs T1b). b. AC
involvement (AC - vs AC +). c. fraction size (2.5 Gy vs 2.0 Gy). d. Tumor BEDGy15 (<65 Gy15 vs ≧ 65 Gy15). Abbreviations: AC: anterior commissure;
AC–: absence of AC involvement; AC+: presence of AC involvement; BED: biologically effective dose.
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according to involvement of AC and fraction size (cate-
gory- A) or another 4 groups (B1-B4) according to
involvement of AC and tumor BED (category-B), i.e.
(A1) no AC involvement with fraction size of 2.5 Gy,
(A2) no AC involvement with fraction size of 2.0 Gy,
(A3) presence of AC involvement with fraction size of
2.5 Gy, (A4) presence of AC involvement with fraction
size of 2.0 Gy [table 3]; (B1) no AC involvement and
BED Gy15≥ 65 Gy15,( B 2 )n oA Ci n v o l v e m e n ta n dB E D
Gy15<6 5G y 15, (B3) presence of AC involvement and
BED Gy15≧65 Gy15, (B4) presence of AC involvement
and BED Gy15 <65 Gy15 [table 4].
There was a statistically significant difference in LC
rates among 4 groups in category-A: 96% vs. 93% vs.
91% vs. 82% respectively at 5 years; 96% vs. 92% vs. 91%
vs.79% respectively at 10 year (p = 0.002) [figure 3a].
Again, similar statistically significant difference in LC
rates was also observed among 4 groups in category-B:
96% vs. 92% vs. 89% vs.82% at 5 years; 96% vs. 92% vs.
89% vs. 80% respectively at 10 year p= 0.003 [figure 3b].
Discussion
In western countries, both definitive RT and conserva-
tive surgery (endoscopic laser surgery/open organ pre-
serving surgery) are accepted standard treatment
modalities for stage one GC [16,17]. A survey conducted
in eleven regions/countries in Asia revealed that in
regions following the ‘British school’ like Hong Kong
and Singapore, RT alone has remained the primary
treatment modality for early laryngeal cancers [2]. As
laser surgery has become more popular since Stener’s
landmark report [18], it is expected that it will be
increasingly employed in local institutions.
Focusing on primary irradiation, there is extensive lit-
erature regarding the efficacy and prognostic factors for
RT in early GC [3-5,19-23]. All data except one series
[24] was retrospective series. Broadly, prognostic factors
can be divided into patient/tumor- as well as treatment-
related factors. Apart from stage, other patient or tumor
prognostic factors have been reported, including tumor
bulk [4,19,25], bilaterality [4,5], AC involvement (see
below), tumor grade [3,26] and hemoglobin level
Table 2 Univariate and multivariate analysis of factors
affecting local control
Parameters Events/
patients
Uni-variate
analysis
Multivariate
analysis
P value HR (95%
CI)
P
value
Age
<61 18/142
61-70 15/153 0.302 _ _
>70 9/138
Sex
Male 41/413 0.445 _ _
Female 1/20
Sub-stage
T1A 28/324 0.24 _ _
T1B 14/109
Grade
Well diff 9/154 1
Mod diff 29/273 0.0001* 1.91 (1.2-
3.85)
0.035*
Poorly diff 4/6 7.5 (3.42-
15.24)
Hb
< 13.0 6/45 0.367 _ _
≥ 13.0 36/388
AC
No 14/236 0.004* 1 0.011*
Yes 28/197 2.34 (1.21-
4.52)
Field size
(cm
2)
<30.5 35/215
30.5-35.5 7/165 0.534 _ _
> 35.5 0/53
Dose size
2.0 Gy 32/256 0.021* 2.17 (1.28-
4.18)
0.035*
2.5 Gy 10/177 1
Tumor BED
< 65 (Gy15) 29/239 0.025* 3.38 (1.29-
7.83)
0.017*
≥ 65 (Gy15) 13/194 1
Tx period
1983-1990 10/115
1991-2000 25/224 0.643 _ _
2001-2005 7/94
Abbreviations: HR = Hazard ratio; CI = confidence interval; Gy = Gray;
diff = differentiated; AC = anterior commissure; BED = Biologically Effective
Dose;
* = statistically significant
Table 3 Category- A: grouping according to AC
involvement and fraction size
AC- AC+
2.5 Gy/fraction 94 (A1) 83 (A3)
2.0 Gy/fraction 142 (A2) 114 (A4)
Table 4 Category- B: grouping according to AC
involvement and BED
AC- AC+
BED ≥ 65 Gy15 94 (B1) 100 (B3)
BED < 65 Gy15 142 (B2) 97 (B4)
Abbreviations: AC = anterior commissure; BED = Biologically Effective Dose
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dose fraction size, total dose, overall treatment time
(OTT) [see below].
The majority of these published data were derived
from patients treated by Cobalt-60 machine or LA gen-
erating 2-4 MV photons [3-5,21,26]. In many RT cen-
ters, these therapy units have been decommissioned.
With a general shift from the use of Cobalt-60 to LA
treatment units, it is anticipated that 6 MV photon
beams generated by LA will become the prevailing
workhorse for treatment in clinical practice [28].
Table 5 showed published results for T1N0 GC treated
with 6 MV photons in the recent two decades.
The impact of AC involvement on the RT treatment
outcome of early GC is still controversial. The so called
AC or Broyle’s tendon is the insertion of vocalis tendon
into thyroid cartilage in the area of AC. This is consid-
ered as a weak point for tumor spread because in this
area, there is no thyroid cartilage perichondrium to
resist tumor spread. Although some data suggested that
AC involvement portended a worse prognosis, it has not
been included in the staging system.
In the recent two decades, many authors identified AC
involvement as one of the independent poor prognostic
factors in LC for T1N0 GC treated by primary RT
[ 4 , 2 1 , 2 9 ] .I nar e c e n tr e p o r tb yS m e ee ta l .[ 3 0 ] ,i tw a s
found that AC involvement was one of the independent
poor prognostic factors for LC as well as cause specific
survival. One explanation is related to the possibility of
‘understaging’ without CT scan staging, as patients
might have a larger tumor burden anteriorly, and in
some cases unrecognized subglottic extension [31]. In
$%
Figure 3 Local control rate according fraction size, tumor BED 15, AC involvement. a. fraction size, together with AC involvement. b.
tumor BED G15, together with AC involvement. Abbreviations: AC: anterior commissure tumor BED Gy15: tumor biologically effective dose N:
patients numbers AC– : absence of AC involvement AC+: presence of AC involvement .
Table 5 Reports in literature on results of T1N0 glottic cancer treated with 6 MV photons
Author year [ref] Patients no Total Dose (Gy) Dose size (Gy) Local Control (5 year)%
Akine et al. 1991 [7] 151 62.5-67.5 2.0-2.4 89
Fein et al. 1996 [27] 43 66 2 95
Foote et al. 1996 [6] 27 63 2.25 100
Lee et al. 2001 [28] 86 66 2 T1a: 82
T1b: 76
Gowda et al. 2003 [36] 100 50-52.5 3.12-3.28 T1a: 93
T1b: 89
Franchin et al. 2003 [20] 323 63-65.2 2.25 T1: 90
Sjögren et al. 2009 [37] 59 60 2.0-2.8 T1a: 87
T1b: 85
current study 433 57.5-66 2.0-2.5 T1a: 92
T1b: 89
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by CT scan, the issue of under-staging should be
minimal.
Another probable reason is the theoretical risk of
under-dosage at the air- tissue interface with the depth-
dose characteristics of 6 MV photons compared with
those of Cobalt-60 beam. This is related to inadequate
t i s s u ep r e s e n ta tt h ea r e ao fA Cw h e r et h en e c ki st h i n ,
as well as lack of electronic equilibrium at the air-tissue
interface which might be more pronounced with high-
energy photons treated with small field size [32,33].
Hence, poorer coverage of the prescribed dose to the
tumor may occur in early glottic tumors with AC invol-
vement, particularly when treated with 6 MV photons.
Sombeck et al. [34] performed a dosimetric evaluation
comparing 6MV photons with Cobalt-60 beam. They
revealed that there was no significant difference in the
dose received at any point along the vocal cords. On the
other hand, a recent study by Spirydovich [35] demon-
strated a significant under- dosage occurring at the air-
tissue interface of larynx treated by 6 MV photons. The
authors performed Monte Carlo dose calculation to CT-
based mathematical neck. They identified that at least
5% of a hypothetical tumor of 3.5 cm
3 received less than
86% of the maximum tumor dose in neck that contains
air cavities in comparison to 91% of the maximum
tumor dose in the homogeneous neck.
However, some other major reports did not reveal the
impact of AC on LC of early glottic cancer [3,5,36,37].
With regard to the impact of dose fraction size for
early glottic disease, there is little controversy that infer-
ior LC is associated with fraction size < 2.0 Gy when
patients are treated once daily, 5 days per week [38,39].
Among the reports published in the literature, the
common contemporary irradiation schedules for T1N0
GC included: 66 Gy in 33 fractions in 6.5 weeks, 63 Gy
in 28 fractions in 5.5 weeks, and 60 Gy in 25 fractions
in 5 weeks [17,40]. In fact, a prospective randomized
study from Yamazaki et al. [24] demonstrated a statisti-
cally superior 5-year LC rate of 92% for patients treated
with fraction size of 2.25 Gy compared with 77% for
those treated with 2.0 Gy.
Besides, many reports have shown that prolonging
OTT in T1N0 GC has an adverse impact on LC and
dose compensation is needed to maintain the tumor
control probability. Indeed, several authors have high-
lighted the complex inter- relationship among the vari-
ables of total dose, fraction size and OTT [41,42].
Fowler [43] commented that according to radiobiolo-
gical principles, even if there would be a positive effect
of increasing total dose or fraction size on LC, and a
strong negative effect of treatment prolongation, these
effects become minimal where the LC was already at a
very high level, because of the plateau of the slope of
the sigmoid- shaped dose-response curve above 70 or
80%. This theoretical postulation has also been verified
by observations reported. Fein et al.[27] and Le et al.
[21] did not observe a relationship between fraction size
and LC. Although there was a trend for higher LC in
patients treated with fraction size of ~2.25 Gy when
compared to smaller fraction size, the difference did not
reach statistical significance. The authors attributed the
l a c ko fd i f f e r e n c et ot h el o wr e c u r r e n c er a t ei nT 1
lesions, thus under- powering the studies to demon-
strate a significant relationship between fraction size
and LC.
The debate over these discrepancies was rebuffed after
the impact of shortening of OTT in LC of H&N cancers
was confirmed in randomized trials with accelerated
schedules. Both the Danish Head and Neck Cancer
Study Group study (DAHANCA 6 & 7) [44] and the
International Atomic Energy Agency (IAEA- ACC) trial
[45] delivered six fractions per week but keeping same
total dose, enabled a treatment of 66 Gy in 33 fractions
to be given in 8 days less than the conventional sche-
dule. They revealed a 10-12% improvement in LC of
H&N cancers (especially for early laryngeal cancer sub-
set) upon shortened OTT. It appeared that by shorten-
ing the OTT, treatment outcome is improved as
accelerated repopulation of tumor clonogens would be
reduced. But these accelerated schedules are also shown
to have more acute radiation toxicity in terms of severe
skin reactions, confluent mucositis necessitating tube
feeding.
In evaluating the efficacy of various fractionation sche-
dules, we opted to test the impact of tumor BEDGy15
which incorporates the components of fraction size,
OTT and total dose. Our analysis shows that tumor
BED ≥ 65 Gy15 is associated with better LC. Table 6
illustrated the common radiation schedules in which
fraction size is > 2.0 Gy, the resulting tumor BEDGy15
would be > 65 Gy15 but the BEDs for both early mucosa
and late normal tissues are well below the correspond-
ing dose constraints for complications [aim at 59-63
Gy10 for acute mucosa; < 117 Gy3 for late normal tissue
respectively] [46].
Since the treatment field size for T1N0 GC is small, it
permits slight hypofractionated schedule without caus-
ing excessive acute radiation toxicity. Shortened OTT
overcomes the accelerated repopulation of tumor
clonogens.
This also supports the current contemporary practice
of fraction dose size > 2.0 Gy (i.e. 2.25 Gy) for treatment
of T1N0 GC by other centers [3,6,20,21,24,37]
To the best of our knowledge, our report is the largest
study on RT outcomes in T1N0 GC primarily treated
with 6 MV photons. As the treatment of choice for
early GC in our institution or Hong Kong at large has
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this represents a relatively unselected cohort of patients.
While this study spans a considerable period of time,
the clinical evaluation and treatment techniques have
been consistent over the years, thus allowing a valid
analysis to be performed. Our results demonstrate that
the LC rate with primary RT with 6 MV photons is
comparable and agrees with other reports of “unremark-
able” treatment outcome difference when comparing
Cobalt-60 beam and 6 MV photons [3,5-7,27].
However, we observe that AC involvement is associated
with a poor LC rate
We suspect that the issue of ‘cold spot’ is more apparent
at the AC region, especially when treated with 6MV
photons. Certainly, further dosimetric evaluation is
needed to validate this suspicion. While involvement of
AC is an adverse prognostic factor, we have shown that
its negative impact can be overcome by delivering a
higher tumor BED (≧ 65 Gy15). In order to achieve this
tumor BED level in conventional schedule of five daily
fractionation each week, we recommend that fraction
size > 2.0 Gy should be utilized. In fact, modest hypo-
fractionation is safe and effective for T1N0 GC in terms
of both LC and morbidity. Having a shorter OTT is
more convenient for patients and is also more cost-
effective for RT facility implication.
Nevertheless, the results need to be interpreted with
caution, because the current report was a retrospective,
single institution study and therefore subjected to biases.
For example, we did not have volume measurements on
tumor, which has been shown in other reports as one of
the important prognostic factors in LC [4,19,25]. In fact,
AC involvement may reflect “tumor bulk” and thus may
represent a surrogate marker for tumor volume. We
suggest the degree of AC involvement should be further
defined to better evaluate and confirm its significance in
outcome prognostication. We also agree with some
authors that the degree of AC involvement should be
incorporated into the new UICC staging system for bet-
ter comparison of results among various studies [47].
Besides, modification of the RT treatment technique like
adding anterior field/anterior oblique field can be con-
sidered to combat under-dosage at AC [3,20].
Conclusions
Our data concur with other published result about the
efficacy of RT with 6 MV photons for T1N0 GC. While
involvement of AC is associated with poor LC rate, its
negative impact could be overcome by delivering a
higher tumor BED through using fraction size of >2.0
Gy. We recommend that fraction size > 2.0 Gy should
be utilized, for radiation schedules with five daily frac-
tions each week.
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